Abstract
Preimplantation genetic diagnosis (PGD) is one of the current options for prevention of genetic disorders and the practical means, in assisted-reproduction technology (ART), to improve in vitro fertilization (IVF) effectiveness. Available PGD evidence for chromosomal disorders shows that at least half of the embryos obtained from IVF patients of advanced reproductive age are aneuploid, suggesting that PGD has clinical relevance for ART. It is also obvious that couples at genetic risk should be provided with information regarding the option of PGD so that they can make their own choices regarding the possibility of avoiding the birth of children with inherited disorders. This article will describe the future of PGD for genetic and chromosomal disorders. We shall demonstrate that PGD may soon not only be an integral part and a required standard of IVF and genetic practices, but will also improve access to human leukocyte antigen identical stem cell transplantation and contribute to the development of cellular therapy for genetic and acquired disorders.